DNA-PKcs Deficiency Sensitizes the Human Hepatoma HepG2 Cells to Cisplatin and 5-fluorouracil Through Suppression of the PI3K/Akt/NF-κB Pathway
Overview
Affiliations
The aim of the present study was to investigate the effects of DNA-PKcs deficiency on the chemosensitivity of human hepatoma HepG2 cells to cisplatin (CDDP) and 5-fluorouracil (5-Fu), and to explore the underlying molecular mechanism. After transfection with DNA-PKcs siRNA or control siRNA, HepG2 cells were exposed to combination treatment of CDDP and 5-Fu. The cell viability, DNA damage, cell apoptosis, intracellular reactive oxygen species and glutathione (GSH) level, expression of apoptosis related proteins, activity of phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway, and nuclear factor-κB (NF-κB) pathways were assessed. The combination of CDDP and 5-Fu had a synergistic cytotoxic effect in HepG2 cells in terms of the cell viability, DNA damage, apoptosis, and oxidative stress level. DNA-PKcs siRNA could sensitize the HepG2 cells to the combined treatment. DNA-PKcs suppression further reduced the Akt phosphorylation level and Bcl-2 expression in HepG2 cells exposed to CDDP and 5-Fu, but enhanced the expression of pro-apoptotic proteins p53 and caspase-3. Moreover, CDDP could inhibit the transcriptional activity of NF-κB through degradation of IkB-α, while 5-Fu alone seemed in some extent increases the NF-κB activity. The combined treatment with CDDP and 5-Fu resulted in significantly decrease of the transcriptional activity of NF-κB, which was further aggravated by DNA-PKcs siRNA treatment. In conclusion, DNA-PKcs suppression had complementary effects in combination with CDDP and 5-Fu treatment in HepG2 cells, which was associated with suppression of NF-κB signaling pathway cascade, activation of caspase-3 and p53, as well as down-regulation of Bcl-2 and GSH.
PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT.
Zhang W, Li W, Yin C, Feng C, Liu B, Xu H Cancer Res. 2024; 84(17):2873-2887.
PMID: 38900943 PMC: 11372366. DOI: 10.1158/0008-5472.CAN-24-0163.
Ma M, Zhou H, Zhang Y, Yuan W, Chen C Int J Med Sci. 2024; 21(4):714-724.
PMID: 38464839 PMC: 10920849. DOI: 10.7150/ijms.91894.
Characters of KRT80 and its roles in neoplasms diseases.
Wei X, Zhao J, Tong H, Cheng S, He N, Song F Cancer Med. 2023; 12(13):13991-14003.
PMID: 37211956 PMC: 10358247. DOI: 10.1002/cam4.6040.
Periyasamy M, Singh A, Gemma C, Farzan R, Allsopp R, Shaw J Oncogene. 2020; 40(6):1077-1090.
PMID: 33323971 PMC: 7116738. DOI: 10.1038/s41388-020-01583-7.
Gu H, Li J, Zhang R Mol Cell Biochem. 2020; 476(2):1283-1292.
PMID: 33226571 DOI: 10.1007/s11010-020-03991-5.